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Abstract
Hippocampal neuron loss is a common neuropathological feature in old age with various
underlying etiologies. Hippocampal sclerosis of aging (HS-Aging) is neuropathologically
characterized by severe CA1 neuronal loss and frequent presence of transactive response
DNA-binding protein of 43 kDa (TDP-43) aggregations. Its etiology is unclear and currently
no standardized approaches to measure HS-Aging exist. We developed a semi-quantitative
protocol, which captures various hippocampal neuron loss patterns, and compared their
occurrence in the context of HS-Aging, TDP-43, vascular and tau pathology in 672 brains
(TDP-43 staining n5 642/672, 96%) donated for the population-based Cambridge City
over-75s Cohort and the Cognitive Function and Ageing Study. HS-Aging was first
evaluated independently from the protocol using the most common criteria defined in
literature, and then described in detail through examination of neuron loss patterns and
associated pathologies. 34 (5%) cases were identified, with a maximum of five pyramidal
neurons in each of over half CA1 fields-of-view (x200 magnification), no vascular damage,
no neuron loss in CA2-CA4, but consistent TDP-43 neuronal solid inclusions and neurites.
We also report focal CA1 neuron loss with vascular pathology to affect predominantly CA1
bordering CA2 (Fisher’s exact, P5 0.009), whereas neuron loss in the subicular end of CA1
was associated with TDP-43 inclusions (Fisher’s exact, P< 0.001) and high Braak stage
(Fisher’s exact, P5 0.001). Hippocampal neuron loss in CA4-CA2 was not associated with
TDP-43. We conclude that hippocampal neuron loss patterns are associated with different
etiologies within CA1, and propose that these patterns can be used to form objective criteria
for HS-Aging diagnosis. Finally, based on our results we hypothesize that neuron loss
leading to HS-Aging starts from the subicular end of CA1 when it is associated with TDP-43
pathology, and that this neurodegenerative process is likely to be significantly more common
than “end-stage” HS-Aging only.
INTRODUCTION
Originally, the term “hippocampal sclerosis” was used to describe
epilepsy patients’ hippocampal changes (50), which can include
neuron loss and gliosis in the CA areas 1, 3 and 4, granule cell dis-
persion, and hypertrophic neurons especially in CA4, with relative
preservation of CA2 and subiculum and lack aggregated proteins
associated with neurodegeneration (6, 9, 10, 47). In contrast, hippo-
campal sclerosis of aging (HS-Aging) is considered as a distinct,
dementia-related pathology (18, 31, 35, 56, 58), neuropathologi-
cally characterized by severe neuron loss and gliosis in the CA1
area. The subiculum may be affected, but CA4, CA3 and are CA2
spared (16, 41, 43). Due to its frequent association with transactive
response DNA-binding protein of 43 kDa (TDP-43)-positive cyto-
plasmic aggregations presence of TDP-43-pathology has recently
been used as an additional criterion for HS-Aging (5, 34).
HS-Aging may also present with neurofibrillary tangles, amyloid
plaques (25, 31), argyrophilic grains (8) and Lewy bodies (7).
Diagnostic criteria of HS-Aging have largely required exclusion of
cases with severe hippocampal tau pathology (8, 14, 28, 42) to dis-
tinguish HS-Aging from severe Alzheimer’s disease cases. A vas-
cular etiology for HS-Aging has also been posited on account of
the high metabolic rate and relatively deficient vascular supply (14)
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that may predispose CA1 neurons to hypoxia (39), but results on
this hypothesis are conflicting (1, 16, 31, 35, 37, 38).
Currently no objective definition of HS-Aging exists and, thus, a
range of potentially distinct pathologies has been included within
this term. In association with differing study settings, this has led to
wide variation of HS-Aging prevalence statistics, from 0.4% (1) to
26% (18) in those with dementia. This complicates the interpreta-
tion, comparison and generalizability of findings. Previous studies
have focused on “end-stage” HS-Aging, while the changes related
to HS-Aging initiation and progression remain unknown. This
study is the first to (1) characterize end-stage HS-Aging, its epide-
miology and pathological associations in a large population-based
cohort and (2) describe detailed patterns of hippocampal neuronal
loss in association with vascular and neurodegenerative pathologies
in the population.
MATERIALS AND METHODS
Study design
The Cambridge City over-75s Cohort (CC75C) and the Medical
Research Council (MRC) Cognitive Function and Ageing Study
(CFAS) are two of the few existing longitudinal population-based
clinicopathological studies. The cohort profiles have been previ-
ously described (13, 19). In brief, CC75C started in 1985 and
recruited 2610 individuals (response rate of 95%) aged 75 years
and above through seven general medical practices in Cambridge,
UK. Recruitment for the brain donation program started shortly
after the second survey, resulting in 241 donations at the time of
this study. The brain donor cohort is representative of the general
population in regard to basic sociodemographic indicators (54).
CFAS recruited 18 226 people aged 65 years and above through
primary care general population lists in six sites in England and
Wales (82% response rate). People who were selected into a 20%
stratified sample from each center for detailed assessment, and all
who underwent this assessment were eligible for the approach for
brain donation. By the time of the current study, 562 CFAS brain
donations had been collected. Brain donors are comparable to the
population sample for most of the basic sociodemographic indica-
tors, except for their older age at death (32).
Neuropathological protocols
In both CC75C and CFAS, after death, brains were retained as
soon as possible. Cerebrum was bisected in sagittal plane. One
hemisphere was dissected coronally into 1 cm slices and frozen at
2808C. The other hemisphere was formalin-fixed for at least six
weeks and dissected coronally into 1 cm slices. Hippocampal (at
the level of the lateral geniculate body), entorhinal cortex (at the
level of the mammillary body), frontal, temporal, parietal and occi-
pital lobe, basal ganglia, thalamus, pons, medulla, cerebellum and
two midbrain tissue blocks were paraffin-embedded. In CC75C,
sections were cut at 9–10 micrometer (mm), in CFAS at 7–9 mm,
and stained with hematoxylin and eosin at the respective study cen-
ters. Standardized neuropathological assessments were carried out
blinded to any clinical data at the respective study centers by clini-
cal neuropathologists.
Severe atherosclerosis, arteriolosclerosis, cerebral macroscopic
infarcts and cortical microinfarcts were assessed as present or
absent with hematoxylin-eosin sides. Anti-tau monoclonal antibody
(CC75C: mAb 11.57, a gift from Prof. C. M. Wischik, University
of Aberdeen (11); CFAS: AT8, recognizing Ser202/Thr205) was
used to immunostain neurofibrillary tangles, neuritic plaques and
dystrophic neurites. The sections were counterstained with Ehr-
lich’s hematoxylin with diaminobenzidine as the chromagen. Rat-
ings for tau-reactive tangles and neuritic plaques per section were
graded as none, mild, moderate or severe, according to the CERAD
protocol (33). These sections were also used to determine the Braak
staging (12). However, due to historical reasons, not all CFAS
cases had a Braak stage assigned (n5 221). Neurofibrillary tangle
pathology in those cases was categorized by using three scores:
15 none and mild tau-reactive tangle pathology in the hippocam-
pus and entorhinal cortex and no tau pathology in the neocortex;
25moderate or severe hippocampal and entorhinal tangle pathol-
ogy and up to mild neocortical tau scores; 35 hippocampus as in
score 2 and moderate or severe tau pathology was found in the
frontal, temporal, parietal or occipital cortex. These scores highly
correlated with the recorded Braak stage (15Braak 0-II, 25Braak
III-IV, 35Braak V-VI) in CFAS (Spearman’s q5 0.798,
P< 0.001). In analysis, the tangle score was used as a Braak stage
estimate if the Braak stage was not known.
The CERAD plaque score refers to the maximum severity of tau
reactive neuritic plaques in the frontal, temporal, entorhinal and
parietal cortex.
Evaluation of the hippocampus and neuron loss
scoring
Work on hippocampal neuron loss was piloted and established
within the CC75C. Two sets of hematoxylin-eosin-stained hippo-
campal sections were available for evaluation from 235 of the total
of 241 brains; one from the CERAD diagnostic set (ten mm), and
the other from the CC75C TDP-43 study (9 mm). Exclusions were
due to missing slides and blocks being used up.
Initial screening was performed under low (40x) and medium
(100x) magnification. For each hippocampal region presence or
absence of acute (tissue rarefication or astrocytosis and presence of
eosinophilic anoxic neurons and white matter vacuolization) or
older (sharply demarcated glial scars or cystic lesions) ischemic
lesions was noted. For the diagnosis of HS-Aging, SH and SRKH
assessed independently, blinded to any clinical or other pathologi-
cal data all available hippocampal hematoxylin-eosin-stained sec-
tions in CC75C, following the most common criteria in literature
(16, 18, 36, 43): severe neuron loss and gliosis in CA1, where neu-
ronal loss was not explained by an infarct, and no obvious neuron
loss in other hippocampal areas was present (Figure 1). HS-Aging
was scored as either absent or present and both raters reached con-
sensus on all cases. They were further reviewed by TMP for
confirmation.
In the next step, neuron loss severity and extent in various
parts of the hippocampus was evaluated in all cases, if the area
was not beyond recognition e.g. due to an abscess or tumor.
Apart from the subiculum, the term “neuron” in this study
refers to Ammon’s horn pyramidal neurons. The categories and
workflow were optimized in several scoring rounds and discus-
sions between SRHK, SH and TMP. Each pyramidal neuron
was identified by its shape, size, position and visible nucleus.
Of the hippocampal regions, CA4 was distinguished from CA3
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by the location of CA4 neurons in the concave of the dentate
gyrus and organization of neurons in CA3. The border between
the narrowest region of the hippocampus CA2 and CA1 was
determined by the widening of the pyramidal cell layer, and the
morphology of cells changing from large ovoid compact CA2
neurons to triangular more scattered CA1 neurons. The transi-
tion from CA1 to the subiculum was identified through a nar-
row cell-free zone between the regions, looser packing of the
pyramidal cell layer in the subiculum than in CA1 and presence
of smaller subicular neurons. The borders between hippocam-
pal subfields are marked in Figure 1A,B. However, neuron pop-
ulations frequently blend in transition zones between the CA
areas. We followed the descriptions and illustrations by Amaral
and Insausti (4) while defining hippocampal sectors.
Magnification of 200x was applied to assess neuron frequencies
in all fields-of-view (ca 9.538 mm2) in the hippocampal regions
(CA4, CA3, CA2, CA1, subiculum). In each region, neuron
frequency was quantified in each field-of-view and assigned a
semi-quantitative severity score: 0–1 neuron; 2–5 neurons; 6–10
neurons; 11–15 neurons. Any neuron frequency, sufficient to reach
the neuron loss severity benchmarks in a field-of-view, was scored
independent from potential underlying causes.
If neuron loss was detected, the extent was recorded for each
severity in the following categories: complete5 neuron loss
affects every field-of-view at 200x magnification of the respec-
tive hippocampal area; sub-complete5 neuron loss affects over
half of the fields-of-view in the respective area; focal5 neuron
loss in less than half of the fields-of-view in the respective area.
If neuron loss in CA1 was not complete, its location was noted
as beginning, middle or end. Borders of these subregions were
based on the total number of fields-of-view used for the evalua-
tion of the case’s CA1. Several categories of neuron loss severity
with differing extent could be marked for a case—not only for
separate CA regions, but also for a subregion. Figure 2 illustrates
schematically for two examples how neuron loss was scored and
recorded.
Reliability and reproducibility of the protocol were tested
through inter-rater evaluation. All cases on both CC75C HE-sets
were first scored independently by two raters (SH, SRKH).
Next, the neuron loss assessment protocol was applied to the
available 452 CFAS cohort cases. Excluded cases lacked routine
neuropathological evaluation (5 donations were too recent) or had
missing hematoxylin-eosin-stained hippocampal slides with used-
up corresponding tissue blocks. Another 15 cases were omitted
from final analysis, because tissue destruction, oxidation, or other
technical shortcomings hindered the assessment, or because the
case code was not identifiable. CFAS cases were assessed by
SRKH, and results were inter-rater evaluated on 10% (n5 45) by
SH with near-perfect agreement for all hippocampal neuron loss
variables. All cases with neuron loss were reviewed and confirmed
(TMP).
Following the neuron loss assessment, the previously diagnosed
HS-Aging cases from CC75C were characterized based on their
neuron loss pattern. Finally, this characteristic neuron loss pattern
was applied to the CFAS cohort to identify its HS-Aging cases.
Immunohistochemistry and assessment of
TDP-43
Hippocampal sections from 642 of 672 CC75C and CFAS cases
that were evaluated for neuron loss, were included in the TDP-43
assessment. Exclusions were due to the hippocampal tissue being
used up. In 15 cases the entorhinal cortex could not be evaluated,
mostly because the cortical structures were damaged/fragmented
during tissue processing.
Hippocampal samples were immunostained with anti-pTDP-43
antibodies (Cosmo Bio Co LTD. pS409/410-2, dilution 1:1000,
antigen retrieval: EBSciences H2800 microwave processor, 15
mins at 988C in a 0.01 M citrate buffer with pH 6.0). Anti-pTDP-
43 immunoreactive neuronal solid cytoplasmic inclusions and short
neurites were evaluated in the hippocampal area including dentate,
CA4, CA3, CA2, CA1 and subiculum, and the entorhinal cortex by
layer. The frequency of inclusions and neurites was scored for each
Figure 1. HS-Aging neuropathological characteristics on hematoxylin-
eosin-staining. A. Hippocampal formation without significant
pathological findings. Hippocampal subfields are marked. B. A
hippocampus with HS-Aging shows severe atrophy and complete neu-
ron loss, and gliosis in the whole CA1 area and subiculum
(arrowheads). Other hippocampal areas appear intact. C. Microglia
and pale eosinophilic astrocytes populate the CA1 region in HS-Aging.
Magnifications: (A, B): 2.5x; scale bar (C): 50 lm. DG5Dentate
Gyrus, Sub5Subiculum.
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area as none, single pathology, mild5 inclusions/neurites seen in
<50% fields-of-view, moderate5 inclusions/neurites seen in
>50% fields-of-view, frequent5 inclusions/neurites seen in all or
nearly all fields-of-view at 200x magnification. Scoring in CC75C
was performed by SH and inter-rater evaluated by SRKH, half of
the scoring in CFAS was done by SH and half by SRKH, and
inter-rater evaluated reciprocally.
Statistical analysis
Inter-rater agreement was assessed calculating Gwet’s Agreement
Coefficient 2 (AC2), which is a paradox-resistant alternative to
Cohen’s kappa (20, 21) when the overall present agreement is high.
Inter-rater analyses were performed blinded on 10% (CC75C:
n5 23; CFAS: n5 45) of donated brains randomly selected but
weighted according to severity scores. Analyses were performed
using Agreestat 2015.1 (Advanced Analytics, Gaithersburg, MD,
USA). The extent of agreement was evaluated using the benchmarks
of Landis and Koch (30): >0.6 indicating substantial agreement and
>0.8 near-perfect agreement. Inter-rater evaluation in both cohorts
and for all hippocampal neuron loss and TDP-43 variables reached
near-perfect agreement (AC2 (95% Confidence Interval [CI]) range:
neuron loss: 0.83 (0.72–0.94) – 0.99 (0.98–1); TDP-43 NSIC: 0.95
(0.87–1) – 0.99 (0.98–1), TDP-43 neurites: 0.91 (0.83–0.98) – 1)).
For several association analyses, the severity of hippocampal
TDP-43 inclusions was dichotomized as present/absent. Scores for
inclusions and neurites were respectively also collapsed for the hip-
pocampus and dichotomized as absent in all hippocampal areas
(dentate, CA4, CA3/2, CA1, subiculum) vs. present in any of these
areas. Analogous, entorhinal cortex inclusions and neurites were
respectively collapsed and dichotomized as absent in all entorhinal
layers vs. present in any of the layers.
Figure 2. Schematic illustration of the hippocampal neuron loss scoring protocol workflow. Example (A) explains the scoring of a case with
extensive severe neuron loss in CA1, and example (B) shows a case with a focal lesion in CA1 bordering CA2.
Population-based hippocampal neuron loss Hokkanen et al
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Continuous data were compared using the Student’s test
(t(degrees of freedom), 95%CI [mean difference]). Association
between categorical variables were tested using the Chi-square test
(v2[degrees of freedom]) or Fisher’s exact test when Cochran’s
restriction applied, and ordinal data was compared using the Mann-
Whitney Rank Sum test (z). Regression analyses were used to eval-
uate the associations between pathologies when taking sex and age
at death into account. Odds ratios (OR) with 95%CI are reported.
Spearman’s correlation (q) coefficient was used to calculate the
correlation strength between the Braak stage and tangle stage
(reported above). a was set at 0.05. Data were analyzed using
STATA14 software (Stata Corporation 2015, Texas, USA).
RESULTS
Table 1 presents the main sociodemographic factors of the whole
cohort (n5 672), and separately for CFAS (n5 437) and CC75C
(n5 235). Out of the 672 cases 64% (n5 427) were female. The
mean age at death was 88.66 6.8 years. By using literature-based
criteria for HS-Aging in CC75C, eleven out of 235 (5%) cases
were identified.
Hippocampal neuron loss prevalence
In this population-based cohort, 116 out of 672 (17%) cases dis-
played any hippocampal CA neuron loss as captured by our proto-
col. Table 2 summarizes the distributions of different neuron loss
severities and locations by hippocampal subfield. Cases with
neuron loss in several subfields are recorded for each category.
Most frequently, neuron loss was observed in CA1 (n5 108, 16%
of all cases). Only 16 (2%) of all cases had neuron loss recorded in
other CA areas than CA1. Under half of these presented with focal
neuron loss in only one sector – five cases with focal neuron loss in
CA2, one in CA3, and one in CA4. Nine cases had neuron loss in
multiple CA subfields.
TDP-43 pathology prevalence
pTDP-43 immunostaining was available for hippocampal sections
of 642 of the total 672 cases (96%). Across CC75C and CFAS,
33% of cases (n5 209/642) had pTDP-43 inclusions in the hippo-
campus or entorhinal cortex (hippocampus: n5 193/639, 30%;
entorhinal cortex: n5 167/627, 27%). 30% of the cohort (n5 192/
642) had pTDP-43 neurite pathology in the hippocampus or ento-
rhinal cortex (hippocampus: n5 178/639, 28%; entorhinal cortex:
n5 152/627, 24%).
Participants with TDP-43 pathology in the hippocampus or ento-
rhinal cortex were significantly older than those without [90.6
(66.1) vs. 87.4 (67.0) years]; [t(626)525.87, 95%CI: 24.20;
22.08, P< 0.001].
HS-aging diagnosis
All of the eleven HS-Aging cases identified in CC75C by initial
screening, were captured within the neuron loss category “no more
than five neurons per fov in over half of the CA1 fov” at 200x mag-
nification. No further cases of the reminder CC75C cohort, which
were not initially evaluated as HS-Aging, reached this level of neu-
ron loss with neuron loss severity being 5 neurons/fov in an
extent of 50% of CA1 fov. When these criteria were applied to
the CFAS cohort, 23/437 (5%) HS-Aging cases were identified. In
all cases the neuron loss involved either the whole CA1 or its mid-
dle and distal thirds with relative sparing of CA1 neurons close to
CA2. For confirmation, all cases which were not associated with
vascular lesions and showed either neuron loss specific to CA1 or
neuron loss extent wide enough to fulfil the proposed criteria for
HS-Aging were re-evaluated, but no additional case fulfilled the
criteria.
Five CC75C/CFAS cases that had neuron loss in multiple CA
areas, also met the HS-Aging CA1 neuron loss threshold. Four of
these five cases were associated with vascular lesions, and one cor-
responded to epilepsy-associated hippocampal sclerosis with den-
tate granular cell dispersion, hypertrophic neurons in CA4, and
patchy neuron loss in CA4, CA3 and CA1. These cases were
excluded from HS-Aging diagnosis.
The HS-Aging criteria also required that ischemic events in CA1
did not explain the severe neurons loss. One such case presented
with a cavitary lesion involving the whole CA1, and the remains of
Table 1. Sociodemographic characteristics.
CFAS n5437 CC75C n5 235 combined n5 672
Female, n (%) 262 (60%) 165 (70%) 427 (63%)
Age at death, mean6 standard deviation 87.06 7.2 91.464.7 88.666.8
CFAS5Cognitive Function and Ageing Study, CC75C5Cambridge City over-75s Cohort, n5number.
Table 2. Numbers of cases with hippocampal neuron loss.
<1
N/fov
1–5
N/fov
6–10
N/fov
11–15
N/fov
n
CA4
Focal 0 0 2 (*1) 0 2 (*1)
Sub-complete 2 0 0 0 2
Complete 1 1 3 0 5
CA3
Focal 0 0 0 2 (*1) 2 (*1)
Sub-complete 1 0 0 1 2
Complete 2 1 1 0 4
CA2
Focal 1 (*1) 1 4 (*4) 0 6 (*5)
Sub-complete 0 0 0 1 1
Complete 0 0 0 0 0
CA1
Focal 16 (*15) 9 (*9) 21 (*21) 11 (*11) 57 (*56)
Sub-complete 6 (*6) 6 (*6) 4 (*3) 6 (*5) 22 (*20)
Complete 10 (*7) 8 (*6) 7 (*7) 4 (*4) 29 (*24)
N5neuron, fov5field-of-view, n5 number, (*) neuron loss only in
the respective subfield.
Hokkanen et al Population-based hippocampal neuron loss
Brain Pathology •• (2017) ••–••
VC 2017 The Authors Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
5
a minor hemorrhage were visible at the subicular end of CA1 was
thus not considered as a HS-Aging case.
HS-aging sociodemographic characteristics
HS-Aging cases had a significantly higher age at death (92.66 5.6
years) compared to the remainder cohort (88.46 6.8 years;
t[670]523.56, 95%CI: 26.52; 21.89, P< 0.001), and a signifi-
cant higher frequency of females (88% vs. 62%, v2(1)5 9.43,
P5 0.002). Both age at death and sex remained significantly pre-
dictive of HS-Aging when considered in logistic regression (sex:
OR:3.54, 95%CI: 1.21–10.33; age: OR:1.10, 95%CI: 1.03–1.17).
TDP-43 pathology and HS-aging
TDP-43 staining was available for 33 out of 34 HS-Aging cases. In
one case, the entorhinal cortex was evaluated but not the hippocam-
pus, because the section was cut too anterior.
All HS-Aging cases were positive for hippocampal pTDP-43
pathology. Dentate inclusions were present in all HS-Aging cases
where assessments were possible. Figure 3A presents the prevalence
and severity of hippocampal inclusions for HS-Aging and no-HS-
Aging cases. Even though neurons are rare in HS-Aging CA1, CA1
inclusions were present in two thirds of the cases. Compared to the
remainder cohort, HS-Aging was highly significantly associated with
inclusions in all hippocampal areas (dentate: 100% vs. 20%,
v2(1)5 109.36, P< 0.001; CA4: 55% vs. 3%, Fisher’s exact,
P< 0.001; CA2/3: 81% vs. 7%, Fisher’s exact, P< 0.001; CA1:
63% vs. 21%, v2(1)5 29.92, P< 0.001; subiculum: 69% vs. 17%,
v2(1)5 51.59, P< 0.001). In all hippocampal areas, also the severity
of inclusions was significantly higher in HS-Aging cases than in the
reminder cohort (dentate: z5211.41, P< 0.001; CA4: z5212.04,
P< 0.001; CA2/3: z5213.45, P< 0.001; CA1: z524.99,
P< 0.001; subiculum: z527.01, P< 0.001) (Figure 3A).
Hippocampal neurites were present in 32/33 HS-Aging cases.
All the positive HS-Aging cases showed neurites in the dentate,
CA1 and subiculum (Figure 3B). Analogous to inclusions, neurite
frequencies in HS-Aging cases were highly significantly different
from the reminder cohort in all hippocampal areas (dentate: 97%
vs. 11%, Fisher’s exact, P< 0.001; CA4: 81% vs. 6%, Fisher’s
exact, P< 0.001; CA2/3: 91% vs. 11%, v2(1)5 145.03, P< 0.001;
CA1: 97% vs. 22%, v2(1)5 89.93, P< 0.001; subiculum: 97% vs.
19%, v2(1)5 103.27, P< 0.001). In all hippocampal locations, the
TDP-43 neurites of HS-Aging cases were significantly more severe
than compared to the reminder cohort (dentate: z5213.62,
P< 0.001; CA4: z5213.72, P< 0.001; CA2/3: z5212.18,
P< 0.001; CA1: z529.88, P< 0.001; subiculum: z5210.82,
P< 0.001) (Figure 3B).
Results for the entorhinal cortex inclusions and neurites were
analogous to the hippocampus. Figure 3C illustrate the prevalence
and severity of inclusions by layer for HS-Aging compared to non-
HS-Aging cases, and Figure 3D shows TDP-43 neurites. Entorhinal
cortex inclusions significantly associated with HS-Aging [97% vs.
Figure 3. TDP-43 inclusions and neurites pathology prevalence and
severity in the hippocampus and entorhinal cortex by HS-Aging status.
All HS-Aging cases were positive for dentate inclusions (A) as well as
neurites (B) were significantly more prevalent and severe in all hippo-
campal regions compared to non-HS-Aging cases. Analogous,
entorhinal cortex inclusions (C) and neurites (D) prevalence and sever-
ity were significantly higher in HS-Aging than the remainder cohort.
**P< 0.001, NSCI5TDP-43-positive neuronal solid cytoplasmic inclu-
sions; SN5TDP-43-positive short neurites; HS5hippocampal sclero-
sis of aging.
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23%, v2(1)5 88.19, P< 0.001], as well as entorhinal cortex neu-
rites [97% vs. 20%, v2(1)5 100.32, P< 0.001].
When controlling for sex and age at death in logistic regression,
the association between TDP-43 pathologies and HS-Aging
remained highly significant (hippocampal neurites: OR:85.68,
95%CI: 11.53–636.61; entorhinal cortex inclusions: OR:93.13,
95%CI: 12.53–692.34; entorhinal cortex neurites: OR: 109.86,
95%CI: 14.81–815.05).
TDP-43 and extensive CA1 neuron loss not
fulfilling the criteria for HS-aging
The case with ischemic complete severe CA1 neuron loss did not
show hippocampal or entorhinal cortex TDP-43 inclusions or neurites.
In contrast, all evaluable cases with less severe neuron loss than HS-
Aging, but in over half of CA1 fields of view, no neuron loss in other
CA areas, and no vascular lesions (n5 8), presented with both TDP-
43 inclusions and neurites in the hippocampus and entorhinal cortex.
Focal CA1 neuron loss distribution
To identify possible further patterns of hippocampal neuron loss, focal
CA1 neuron loss without neuron loss in other CA areas was evaluated
in more detail. Table 3 presents the distribution of CA1 neuron loss
only, by severity and location within CA1. Out of 56 cases, neuron
loss was located in the proximal third of CA1 bordering CA2 in 11
cases, in the CA middle part in 13 cases, and in the distal end of
CA1 in 32 cases. In 20 (36%) cases, CA1 focal neuron loss was asso-
ciated with vascular pathology.
The beginning, middle and end sector of CA1 with focal neuron
loss were differentially affected by vascular pathology [n5 7/11
(64%), n5 7/13 (54%) and n5 6/32 (19%) respectively; Fisher’s
exact, P5 0.008, Figure 4E]. When comparing focal neuron loss
between CA1 subfields (two by two comparisons), we demon-
strated that focal neuron loss near CA2 was significantly more fre-
quently related with well demarcated scar-like gliosis (Figure
4A,B) than the subicular end of CA1 (64% vs. 19%, Fisher’s exact,
P5 0.009). Results were similar when comparing lesions in the
middle third to those in the subicular end of CA1 (54% vs. 19%,
Fisher’s exact, P5 0.025). Vascular lesions were equally common
in focal neuron loss bordering CA2 as in the middle CA1 section
(64% vs. 54%, Fisher’s exact, P5 0.473). In contrast, focal neuron
loss in the subicular end of CA1 showed disseminated diffuse neu-
ron loss pattern with less aggressive gliosis than focal lesions bor-
dering CA2 (Figure 4C,D).
Focal CA1 neuron loss and TDP-43
TDP-43 immunostaining was possible in 51 of 56 cases with focal
CA1 neuron loss. Non-vascular CA1 focal neuron loss was signifi-
cantly associated with inclusions: 32% (n5 6/19) of the cases with
a vascular lesion presented with TDP-43 inclusions, whereas 69%
(n5 22/32) of the cases with focal neuron loss without recorded
ischemic pathology were positive for TDP-43 inclusions- and/or
neurites (v2[1]5 6.65, P5 0.01).
TDP-43 pathology was also strongly associated with the location
of CA1 focal neuron loss: none of the ten cases that had a focal
CA1 lesion bordering CA2 presented with inclusions or neurites,
whereas 39% (n5 5/13) of the cases with a focal lesion in the mid-
dle third of CA1 were positive for inclusions (Fisher’s exact,
P5 0.038) and 31% (n5 4/13) for neurites (Fisher’s exact,
P5 0.081). 82% (n5 23/28) of the cases with a focal lesion in the
CA1 sector bordering the subiculum showed TDP-43 inclusions
(Fisher’s exact, P< 0.001), and 79% (n5 22/28) neurites (Fisher’s
exact, P< 0.001) (Figure 4E).
Figure 4. Focal neuron loss characteristics in different locations of
the CA1 sector. (A) Focal neuron loss due to a microinfarct in the
beginning of the CA1. The circle marks (B), one field-of-view at 200x
magnification showing a localized, well circumscribed complete loss
of neurons, and a glial scar. (C) Focal neuron loss in the subicular end
of CA1, possibly associated with neurodegeneration. Neurons are pre-
served more proximal of the lesion (arrowheads). The circle marks
(D), one field-of-view at 200x magnification showing disseminated
gliosis and severe neuron loss, without indications of a microinfarct.
Scale bars: (A, C): 200 lm; (B, D): 100 lm. (E) Among cases with neu-
ron loss, lesions in the CA2-bordering third of CA1 are most likely
affected with ischemia (*P50.009), whereas neuron loss with TDP-
43 inclusions associates with the subicular end of CA1 (**P< 0.001).
NSCI5 neuronal solid cytoplasmic inclusions.
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All 22 cases with focal non-ischemic CA1 neuron loss that were
positive for hippocampal TDP-43 inclusions also had inclusions in
the entorhinal cortex.
Neuron loss in CA4-2 and TDP-43
TDP-43 staining was available in 14 cases out of the 16 cases
which had any category of neuron loss in CA4, CA3 or CA2. Four
of these (29%) were positive for hippocampal inclusions, not differ-
ing from the remainder population (30%, n5 189/625, Fisher’s
exact, P5 0.578). Equivalently, 4/14 (29%) cases with neuron loss
in CA4-2 showed hippocampal neurites, whereas cases without
neuron loss in these areas had a comparable neurite prevalence of
28% (n5 174/625, Fisher’s exact, P5 0.578). No difference was
observed in the prevalence of entorhinal cortex inclusions or neu-
rites between cases with CA4-2 neuron loss and the remainder
cohort (inclusions: 28%, n5 4/14 vs. 27%, n5 163/613, Fisher’s
exact, P5 0.537; neurites: 36%, n5 5/14 vs. 24%, n5 147/613,
Fisher’s exact, P5 0.235).
HS-aging and other pathologies
Vascular pathologies were prevalent in this cohort. HS-Aging was
not associated with any of the evaluated CERAD vascular patholo-
gies compared to the remainder [atherosclerosis: 33% vs. 32%,
v2(1)5 0.01, P5 0.917; arteriolar sclerosis: 81% vs. 75%,
v2(1)5 0.53, P5 0.468; cerebral infarcts >10 mm: 61% vs. 52%,
v2(1)5 0.52, P5 0.470; cerebral infarcts< 10 mm: 44% vs. 35%,
v2(1)5 0.50, P5 0.478; temporal microinfarcts: 0% vs. 9%,
Fisher’s exact, P5 0.387; frontal microinfarcts: 20% vs. 8%, Fish-
er’s exact, P5 0.195; parietal microinfarcts: 20% vs. 14%, Fisher’s
exact, P5 0.426; occipital microinfarcts: 20% vs. 15%, Fisher’s
exact, P5 0.474].
HS-Aging was not significantly associated with CERAD score:
24% (n5 8/34) had a CERAD score of zero, 18% (n5 6/34) a
score A, 41% (n5 14/24) a score B and 18% (n5 6/34) a score C
(Fisher’s exact, P5 0.142).
Eleven HS-Aging cases (32%) presented with Braak stage 0-II,
ten cases (29%) with stages Braak III-IV, and 13 cases (38%) with
Braak V-VI. The distribution differed significantly from the remain-
der population [v2(2)5 6.40, P5 0.041], with HS-Aging showing a
lower prevalence of Braak III-IV stages and higher prevalence of
Braak 0-II and V-VI stages compared to non-HS-Aging cases (Braak
0-II: 28%, III-IV: 49%, V-VI: 22%). However, when controlling for
sex and age at death in logistic regression analysis, Braak stage did
not significantly predict HS-Aging (OR: 1.08, 95%CI: 0.65–1.79).
Focal CA1 neuron loss and other pathologies
Focal CA1 neuron loss did not associate significantly with any of
the CERAD vascular pathologies, neither when comparing
ischemia-related focal CA1 neuron loss to non-vascular neuron
loss, nor when comparing neuron loss by location within CA1.
Focal neuron loss at the subicular end of CA1 was significantly
associated with a higher Braak stage compared to neuron loss in the
beginning of CA1 (Fisher’s exact, P5 0.001). No case with neuron
loss at the subicular end of CA1, had a Braak stage of 0-II. However,
hippocampal tangle severity did not show a significant association
with the focal neuron loss location (Fisher’s exact, P5 0.304). In
contrast to the Braak stage, focal CA1 neuron loss proximal to CA2
compared to neuron loss at the subicular end of CA1 did not differ
significantly in CERAD score (Fisher’s exact, P5 0.171).
DISCUSSION
This study evaluates in detail the hippocampal neuron loss pattern
and TDP-43 pathology in a population-based cohort of older peo-
ple. We report end-stage HS-Aging to be characterized by quantifi-
able measures of neuron loss location, extent and severity in
Table 4. Key pathological characteristics of end-stage hippocampal sclerosis of aging.
Neuron loss location: CA1; 6subiculum; sparing of CA4–2
Extent: 50% of CA1 fov at 200x magnification
Severity:  five neurons per fov
TDP-43 Solid neuronal inclusions: present in the dentate of all cases
highly prevalent in the entorhinal cortex
Dystrophic short neurites: highly prevalent in the hippocampus and entorhinal cortex
Tau No association with the Braak stage or CERAD plaque score
Vascular No association with atherosclerosis, arteriolar sclerosis, cerebral infarcts, hippocampal microinfarcts or cortical microinfarcts
Fov5field of view; CERAD5Consortium to Establish a Registry for Alzheimer’s Disease.
Table 3. Focal CA1 neuron loss characteristics, excluding cases with neuron loss in other CA areas.
CA1 location <1 N/fov 1–5 N/fov 6–10 N/fov 11–15 N/fov n
n515 n59 n521 n511
nv v nv v nv v nv v
Beginning 1 3 1 2 1 2 1 0 11
Middle 1 3 3 1 1 2 1 1 13
End 4 3 1 1 13 2 8 0 32
N5 neuron; fov5 field of view; n5 number; v5 vascular; nv5 non-vascular.
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association with presence of dentate TDP-43 inclusions (Table 4).
We show that there are neuron loss patterns within the hippocampal
CA1 in the older population associated with distinct pathologies:
focal CA1 neuron loss bordering CA2 was predominantly associ-
ated with vascular lesions, whereas neuron loss in the subicular end
of CA1 associated with TDP-43 and a high Braak stage.
There are methodological limitations to this study that need to
be considered. In a research setting, neuron loss within a given tis-
sue or structure is typically assessed with stereological methods
(49, 52), which provide accurate and consistent measures. How-
ever, because of the required equipment and time, stereology is not
compatible with routine neuropathological diagnostic methods, or
for application to cohorts of many hundreds of cases. Furthermore,
stereology requires thick sections, thus limiting tissue availability
for other purposes. Because of these considerations, we designed a
protocol for capturing different hippocampal neuron loss patterns
relying on routine hematoxylin-eosin-sections.
Although measures of vascular and tau pathology followed the
CERAD protocol (33), different pathologists were responsible for
brain examinations, leading to potentially subjective interpretations,
and varying grades of precision and completeness of the form. Fur-
thermore, staining methods may have changed since the start of the
studies, enhancing the risk of variations in scorings. These mea-
surement errors are present in all long term multi-center pathologi-
cal studies without inter-rater evaluation. By following an
internationally standardized protocol comparability between studies
is maximized when keeping in mind its limitations. We comple-
mented the lack of consistency in Braak staging by a measure based
on the available hippocampal and cortical tangle scores which cor-
related significantly with the “standard” Braak stage, but recognize
that this is not an ideal solution.
We may have underdiagnosed focal hippocampal lesions and
HS-Aging, as only one or a few sections from each hippocampus
from one hemisphere were assessed. HS-Aging is reported to also
occur segmentally (24), and in a quarter of cases unilaterally (35,
53, 58). However, the size and nature of this large, truly
population-based cohort derived from population representative
studies should mitigate this limitation, and the detected associations
related to various neuron loss patterns in the hippocampus and
presence of TDP-43 pathology are considered reliable.
This study focused on presence/absence of Ammon’s horn pyram-
idal neurons. Minor discrepancies in neuron loss scoring occurred,
and reasons were discussed between SRKH, SH and TMP. These
included variation in decisions on CA area borders between each
other and especially between CA1 and the subiculum, and some dif-
ficulties in decisions on counting neuron-like shapes as neurons or
not. However, results of our inter-rater evaluations indicated that the
neuron counts in this study are reliable and reproducible.
This study provides important strengths to investigate its aims.
CA1 neuron loss is the key characteristic of old-age HS-Aging, as
initially described by Dickson et al (18), but little systematic
research on the pattern and severity of neuron loss within HS-
Aging has been conducted before this work. Recently, presence of
TDP-43-pathology in the hippocampus has been used as an addi-
tional diagnostic criterion (5, 34). Unfortunately, existing defini-
tions of HS-Aging are still diverse, and the potential variable
aetiologias behind hippocampal neuron loss add to this confusion.
Our initial assessment of HS-Aging in the CC75C cohort was
done independently by two raters according to CA1 neuron loss
and gliosis descriptions in literature (16, 18, 36, 43), and diagnosis
was confirmed by an experienced neuropathologist. Because all
three raters agreed on all the cases, the likelihood of false HS-
Aging case inclusion or exclusion is low. When these HS-Aging
cases were compared to hippocampal neuron loss scorings, a CA1
neuron loss threshold of “maximal five pyramidal neurons in each
field-of-view in over half of the CA1 fields-of-view at x200 magni-
fication” defined the proposed HS-Aging in our study. Interestingly
all these cases presented with hippocampal TDP-43 pathology.
Thus, in these two population-based cohorts, key HS-Aging charac-
teristics comprise neuron loss selectivity (sparing of CA2-4), ische-
mia (not present), severity (<5 neurons/field-of-view), extent
(>50% CA1 fields-of-view) and TDP-43 inclusions (present).
Selectivity of neuronal loss differentiates HS-Aging from HS-
epilepsy: in HS-Aging, hippocampal neuronal loss is seen in the
CA1 and subiculum only, whereas in HS-epilepsy neuronal loss
often affects the CA3 and CA4, and the granular cell layer shows
irregularities, while the subiculum is often not affected (6, 9, 10,
47). Although some studies on HS-Aging explicitly state a sparing
of CA2/3 in HS-Aging diagnosis (16, 17, 24, 27, 31, 55), others
include cases which present with neuron loss also in other hippo-
campal sectors than the CA1 and subiculum (15, 29, 43, 44, 57,
58). Frequently, the term “selective” is used for CA1 neuron loss
and gliosis, but how potential lesions in other CA areas are consid-
ered is not further specified (for example (2, 7, 26, 35)). A consen-
sus study categorized hippocampal lesions into six types; type four,
characterized by “complete neuronal loss from CA1 because of
neurodegeneration” and type three, described as “patchy diffuse
neuronal degeneration in CA sectors associated with or without
neuronal lesions of neurodegenerative origin” were both suggested
to be recognized as HS-Aging (45). Cases with neuron loss outside
the CA1 and subiculum may not necessarily reflect the same dis-
ease processes that result in total neuron loss specifically in CA1 in
older people, supported by our results of them not significantly
associating with TDP-43 pathology. Noticeable neuron loss in
CA4-2 could be regarded as evidence against HS-Aging.
The original description of HS-Aging by Dickson et al include
“one case [where] the lesion was more extensive and associated
with partial cyst formation” (18). Cavitary lesions are discussed con-
troversially in literature - cases with CA1 cavitary lesions are either
specifically included (36) or excluded (14, 42, 56, 58), or not
addressed in HS-Aging diagnosis. In this study, only one case in the
CFAS cohort presented with an extensive cavitary lesion in CA1
and met the HS-Aging neuron loss threshold, but was not regarded
as HS-Aging, because of the co-occurrence of vascular features
including the cavern, characteristic patterns of gliosis and vacuoliza-
tion, sharp demarcation of the gliotic neuron loss area toward the
neighboring tissue and presence of micro-hemorrhages and
hemosiderin-containing macrophages. This case also lacked hippo-
campal TDP-43 pathology as did all of the cases with focal vascular
lesions bordering CA2. We also could not confirm an association
between any assessed vascular pathologies – whether in hippocam-
pus, temporal lobe or elsewhere – and HS-Aging. Although it is the-
oretically possible that exclusion of vascular pathology from HS-
Aging definition may have biased this finding, only the one vascular
case described above would have met the neuron loss criteria of
HS-Aging, and would therefore not have affected statistical analy-
ses. Findings of this population-based study suggest that classical
cerebrovascular pathologies are not primarily linked to HS-Aging.
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Furthermore, even though CA1 is indisputably predisposed to ische-
mic lesions by its vascularization anatomy, results from rodent and
non-human primate studies have shown that transient cerebral hypo-
perfusion leads primarily to neuron loss in the junction of CA1/
CA2, whereas neurons in the subicular end of CA1 are not affected
(40, 48). Considering these findings, our results suggest that classi-
cal vascular brain lesions or transient hypoperfusion are unlikely
directly linked with development of HS-Aging.
A characteristic frequently included in HS-Aging definition in lit-
erature is the absence of other neurodegenerative pathologies possi-
bly accounting for the CA1 neuron loss, or neuron loss being out of
proportion to neurofibrillary tangle pathology (1, 3, 22), due to its
association with hippocampal atrophy and CA1 neuron loss (46,
51). However, this kind of definition is likely to increase the subjec-
tivity of HS-Aging diagnosis and thus dependence on the patholo-
gist’s personal opinion. In our study, HS-Aging cases did not show
high hippocampal tangle scores, probably due to the very low num-
ber of neurons in the CA1. The stains used did not allow us to eval-
uate reliably the possible presence of the “ghost” tangles.
Regardless of the hippocampal tau pathology, we do not assume
HS-Aging and Alzheimer’s disease to be mutually exclusive. We
intended to avoid selection bias based on subjective expectations of
pathological associations, but rather to describe features capturing
HS-Aging irrespective of a potential additional Alzheimer’s disease.
This approach gives a possibility to test the relationship between
other pathologies and the strictly defined HS-Aging. This view is
supported by the lack of association between the severe selective
neuron loss seen in the context of HS-Aging and parameters tradi-
tionally related with Alzheimer’s disease. In contrast, in this unse-
lected population-based study, no case without TDP-43 pathology –
apart from one case with a hippocampal infarct – reached the neuron
loss severity and distribution identified for HS-Aging.
Because we used criteria for definitive severe (end-stage) HS-
Aging in CC75C according to most common descriptions in litera-
ture (16, 18, 36, 43), it is likely, that potential “pre-HS-Aging”
cases with less neuronal loss were not categorized as HS-Aging.
Our finding of TDP-43 pathology in all cases that were captured
with our neuron loss evaluation protocol for extensive CA1 neuron
loss, but who did not fulfill the criteria for HS-Aging, is suggestive
of this situation. However, the strict HS-Aging criteria minimized
false-positive cases in the HS-Aging category, and in association
with the more detailed neuron loss pattern evaluation and TDP-43
assessment allowed us to generate hypotheses on their association.
Interestingly, focal neuron loss characteristics differed signifi-
cantly depending on their location within CA1: lesions bordering
CA2 presented more frequently with a well-demarcated area of
severe neuron loss and/or glial scar, that is, findings of likely vascu-
lar lesions. None of the cases with CA1 lesions bordering CA2 pre-
sented with TDP-43 or neurites. Our findings are in line with the
location of hypoxic lesions reported in animal studies (40, 48), as
well as results reported by Hatanpaa et al (23), who observed
epilepsy-associated and ischemic injury to be common in the proxi-
mal and middle CA1.
In contrast, focal neuron loss in CA1 bordering the subiculum
was mostly diffuse with ill-defined borders, and was less severe.
Based on the morphology and its strong association with hippo-
campal TDP-43 pathology, this focal neuron loss in the end of
CA1 is hypothesized to be of primary neurodegenerative origin. In
line with these results, Hatanpaa et al (23) described severe neuron
loss in FTLD to be consistently located in the distal CA1. Our find-
ings on more extensive CA1 neuron loss reflect the pattern
observed in focal lesions.
Our pathological data are cross-sectional and no direct conclu-
sions on neuron loss progression can be made. However, in the
older population there seems to be a specific pattern of neurodegen-
eration associated with TDP-43 most commonly affecting the sub-
icular end of CA1, while neurons close to CA2 are relatively
spared. It can be hypothesized, that neuron populations within dif-
ferent CA1 subfields differ in their vulnerability to vascular and pri-
mary neurodegenerative damage. Based on these findings we
hypothesize that HS-Aging progresses from focal diffuse neuron
loss in the subicular end of CA1 toward CA2. Longitudinal studies
will be required to investigate this hypothesis further and biochemi-
cal work is necessary to identify possible features and differences
in respective etiological pathways and to explore the roles of vascu-
lar disease, excitotoxicity, cytoskeletal changes and TDP-43 in neu-
ronal loss and HS-Aging.
In summary, we describe neuron loss and TDP-43 pathology
characteristics in HS-Aging, which could be used as objective end-
stage HS-Aging criteria, enhancing consistency and comparability
between future studies on this disorder. We present distinct patterns
of primary neurodegenerative and vascular hippocampal neuron
loss, which may contribute to understanding the specific vulnerabil-
ity of different hippocampal neuron populations to neurodegenera-
tive changes and aging. We suggest a neurodegenerative neuron
loss progression from “pre-HS-Aging,” starting at the subicular end
of CA1 in association with TDP-43 pathology, to HS-Aging. Fur-
ther research is needed to explore these hypotheses.
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